Given the finding that activation of all PPARs, but especially PPARγ, has salutary effects on neurodegenerative disorders including AD (19) and that a promising role of PPARα in AD therapy has emerged (10, 37), we wondered whether a PPARα-specific agonist could interfere with the observed hAPP-mediated decrease in PPARα target genes’ expression. This evidence concerns the gene PPARG and Alzheimer disease.